Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
Not yet recruitingOBSERVATIONAL
Enrollment
300
Participants
Timeline
Start Date
February 15, 2025
Primary Completion Date
January 15, 2027
Study Completion Date
May 15, 2027
Conditions
TNBC - Triple-Negative Breast Cancer
Trial Locations (1)
200032
Fudan University Shanghai Cancer Center, Shanghai
All Listed Sponsors
lead
Fudan University
OTHER
NCT06798506 - Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter